Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostic company Myriad Genetics (NASDAQ:MYGN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Myriad's business and see what CAPS investors are saying about the stock right now.

Myriad Genetics facts 

Headquarters (founded)

Salt Lake City (1991)

Market Cap

$2.69 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$412.4 million

Management

President/CEO Dr. Peter Meldrum (since 1991)

CFO James Evans (since 2007)

Compound Annual Revenue Growth (over past five years)

48.4%

Cash and Short-term Investments / Debt

$402.1 million / $0

Other Highly Rated Biotech Stocks

Amgen (NASDAQ:AMGN)

Genzyme (NASDAQ:GENZ)

CAPS Members Bullish on MYGN Also Bullish on

Johnson & Johnson (NYSE:JNJ)

Apple (NASDAQ:AAPL)

CAPS Members Bearish on MYGN Also Bearish on

Dendreon (NASDAQ:DNDN)

Amazon.com (NASDAQ:AMZN)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS.

Over on CAPS, some 92% of the 404 members who have rated Myriad believe the stock will outperform the S&P 500 going forward. These bulls include All-Star toolowihope, who is ranked in the top 0.5% of our community, and FitzColinGerald.

In late April, toolowihope tapped Myriad as a particularly special situation:

The pharmaceutical spin-off should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.

In a more recent pitch, FitzColinGerald offers myriad reasons to like the stock as a pure prognostication play:

Myriad Genetics is a health care company that specializes in the marketing of prognostic medicine products. Such products include COLARIS and TheraGuide 5-FU, which measure a person's susceptibility to colon cancer and a person's response to 5-FU-based chemotherapy, respectively. These products are becoming increasingly important, as patients wish to assess their potential risks with certain diseases and treatments.

What do you think about Myriad, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned in this article. Johnson & Johnson is a Motley Fool Income Investor pick. Amazon and Apple are selections of Stock Advisor. The Fool's disclosure policy always gets a perfect score.